Poxel SA (POXEL) - Total Assets
Based on the latest financial reports, Poxel SA (POXEL) holds total assets worth €5.00 Million EUR (≈ $5.85 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Poxel SA debt service capacity to assess how comfortably operating cash covers total debt obligations.
Poxel SA - Total Assets Trend (2010–2024)
This chart illustrates how Poxel SA's total assets have evolved over time, based on quarterly financial data. See Poxel SA net assets for net asset value and shareholders' equity analysis.
Poxel SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Poxel SA's total assets of €5.00 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 24.5% |
| Accounts Receivable | €10.50 Million | 70.4% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €1.00K | 0.0% |
| Intangible Assets | €2.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Poxel SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Poxel SA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Poxel SA's current assets represent 99.5% of total assets in 2024, a decrease from 99.6% in 2010.
- Cash Position: Cash and equivalents constituted 24.5% of total assets in 2024, down from 74.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 70.4% of total assets.
Poxel SA Competitors by Total Assets
Key competitors of Poxel SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Poxel SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 0.26 | 4.51 |
| Quick Ratio | 0.26 | 0.26 | 4.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-14.03 Million | €-15.42 Million | €43.45 Million |
Poxel SA - Advanced Valuation Insights
This section examines the relationship between Poxel SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.34 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | 209.5% |
| Total Assets | €14.93 Million |
| Market Capitalization | $12.74 Million USD |
Valuation Analysis
Near Book Valuation: The market values Poxel SA's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Poxel SA's assets grew by 209.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Poxel SA (2010–2024)
The table below shows the annual total assets of Poxel SA from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €14.93 Million ≈ $17.45 Million |
+209.54% |
| 2023-12-31 | €4.82 Million ≈ $5.64 Million |
-86.11% |
| 2022-12-31 | €34.71 Million ≈ $40.58 Million |
-36.76% |
| 2021-12-31 | €54.89 Million ≈ $64.17 Million |
-15.66% |
| 2020-12-31 | €65.08 Million ≈ $76.08 Million |
-9.99% |
| 2019-12-31 | €72.30 Million ≈ $84.53 Million |
-31.48% |
| 2018-12-31 | €105.52 Million ≈ $123.36 Million |
+58.07% |
| 2017-12-31 | €66.75 Million ≈ $78.04 Million |
+32.70% |
| 2016-12-31 | €50.30 Million ≈ $58.81 Million |
+7.38% |
| 2015-12-31 | €46.85 Million ≈ $54.77 Million |
+238.84% |
| 2014-12-31 | €13.83 Million ≈ $16.16 Million |
+12.72% |
| 2013-12-31 | €12.27 Million ≈ $14.34 Million |
+49.90% |
| 2012-12-31 | €8.18 Million ≈ $9.57 Million |
-19.58% |
| 2011-12-31 | €10.17 Million ≈ $11.90 Million |
-19.86% |
| 2010-12-31 | €12.70 Million ≈ $14.84 Million |
-- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more